NEW DELHI : A World Health Organization (WHO) panel on Friday gave its green signal to monoclonal antibodies therapy for management of two categories of covid-19 patients.
A treatment combining two antibodies (casirivimab and imdevimab) is recommended for two specific groups of patients with covid-19 by a WHO Guideline Development Group (GDG) panel of international experts.
Casirivimab and imdevimab are monoclonal antibodies that when used together bind to the SARS-CoV-2 spike protein, neutralizing the virus’s ability to infect cells.
The panel recommended it for patients with non-severe covid-19, who are at highest risk of hospitalization and those with severe or critical covid-19 who are seronegative, meaning they have not mounted their